BLA number
125196
FDA Purple Book product · 351(a) biologic
PegIntron/ Rebetol Combo Pack
peginterferon alfa-2b and ribavirin
PegIntron/ Rebetol Combo Pack, BLA 125196, is listed in the FDA Purple Book as a 351(a) biologic. This page consolidates 4 exact FDA presentation rows, and no exact reference-product relationship is asserted. It separates the BLA applicant from any unverified manufacturer and does not infer clinical labeling, pharmacy substitution, commercial availability, or patent conclusions.
351(a)BLA 125196 4 presentationsDiscVoluntarily Revoked Schering Corporation a subsidiary of Merck & Co., Inc.
Approved
Jun 13, 2008
License type
351(a)
Marketing
Disc
Listed patents
0
PegIntron/ Rebetol Combo Pack (peginterferon alfa-2b and ribavirin) is Schering Corporation a subsidiary of Merck & Co., Inc.'s FDA-licensed 351(a) biologic under BLA 125196, approved in 2008. No 351(k) product in the loaded Purple Book family data explicitly references PegIntron/ Rebetol Combo Pack; that bounded result is not a claim about future reference-product eligibility.
Sourced from the FDA Purple Book · verified Jul 02, 2026
What this Purple Book record establishes
Regulatory interpretation
Regulatory role
351(a) biologic
Applicant
Schering Corporation a subsidiary of Merck & Co., Inc.
Applicant is not automatically the physical manufacturer.
Presentations
4
Exact FDA presentation rows under this BLA.
Approval
Jun 13, 2008
Reference product
Not stated
PegIntron/ Rebetol Combo Pack is an FDA-licensed 351(a) biologic.
No 351(k) product in the loaded Purple Book family data explicitly references PegIntron/ Rebetol Combo Pack.
Substitution boundary
The absence of a linked 351(k) record is a bounded database result, not proof that the product can never serve as a reference product.
Key dates
Licensure & exclusivity
Approval
Approval date of this BLA submission.
Jun 13, 2008
18 yr 5 mo ago
Today
Strengths & presentations
4 FDA presentation rows · BLA 125196
Strength
50MCG/0.5ML & 200MG
Dosage form
Not listed
Route
Not listed
Presentation
Not listed
Center
CDER
License number
0994
Product number
001
Submission type
Original
Supplement number
Not listed
Change type
Not listed
Strength
80MCG/0.5ML & 200MG
Dosage form
Not listed
Route
Not listed
Presentation
Not listed
Center
CDER
License number
0994
Product number
002
Submission type
Original
Supplement number
Not listed
Change type
Not listed
Strength
120MCG/0.5ML & 200MG
Dosage form
Not listed
Route
Not listed
Presentation
Not listed
Center
CDER
License number
0994
Product number
003
Submission type
Original
Supplement number
Not listed
Change type
Not listed
Strength
150MCG/0.5ML & 200MG
Dosage form
Not listed
Route
Not listed
Presentation
Not listed
Center
CDER
License number
0994
Product number
004
Submission type
Original
Supplement number
Not listed
Change type
Not listed
Exact presentation matrix
One row per FDA presentation under this exact BLA. Missing cells remain unavailable rather than being borrowed from another product.
| Product | Strength | Dosage form | Route | Presentation | Licensure | Marketing |
|---|---|---|---|---|---|---|
| 001 | 50MCG/0.5ML & 200MG | Not listed | Not listed | Not listed | Voluntarily Revoked | Disc |
| 002 | 80MCG/0.5ML & 200MG | Not listed | Not listed | Not listed | Voluntarily Revoked | Disc |
| 003 | 120MCG/0.5ML & 200MG | Not listed | Not listed | Not listed | Voluntarily Revoked | Disc |
| 004 | 150MCG/0.5ML & 200MG | Not listed | Not listed | Not listed | Voluntarily Revoked | Disc |
Exact-source evidence coverage
Labeling & approval review
Current product label
Exact-source research required
No exact-BLA label candidate is stored for this record. Approved uses, dosing, and warnings are intentionally unavailable and queued for exact-source research.
FDA approval evidence
Not applicable to 351(a)
A biosimilar totality-of-evidence summary is not applicable to this 351(a) record. Product-specific clinical content still requires an exact-BLA label or review source.
Human review pending
Automated BLA-level interpretation has not been marked human-reviewed. The research queue contains 1 exact-source task. Labeling and approval-review claims stay unavailable until their own match gate passes.
Reference product family
Biosimilars & interchangeables
The current record does not expose a reference-product name or an exact linked 351(k) family for PegIntron/ Rebetol Combo Pack.
No reference product is stated in this exact Purple Book row. This is a bounded snapshot result, not proof of real-world absence.
Published patents
BPCIA patent list
No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.
Practical characteristics and limits
Source-bounded interpretation
Presentation coverage
4 exact FDA presentation rows are consolidated under this BLA rather than split across duplicate pages.
Administration fields
The loaded Purple Book rows do not state a route or dosage form; the page does not borrow them from another BLA.
Applicant boundary
Schering Corporation a subsidiary of Merck & Co., Inc. is the listed BLA applicant. The page does not relabel the applicant as manufacturer, labeler, distributor, or commercial supplier without an exact product-specific source.
Regulatory comparison
PegIntron/ Rebetol Combo Pack is an FDA-licensed 351(a) biologic. Family comparisons preserve each BLA's own designation and do not use Orange Book therapeutic-equivalence terminology.
Source provenance
FDA Purple Book data
Source kind · Advanced Search
Checked Jul 02, 2026- advanced-searchAdvanced Search · Jul 02, 2026
- monthly-downloadMonthly download · Jul 02, 2026
What this record does not establish
- Purple Book marketing status is a regulatory field, not real-time commercial inventory or launch status.
- The listed applicant or BLA holder is not automatically the product’s physical manufacturer, labeler, or distributor.
- Biosimilar status and interchangeability are distinct FDA designations; neither is a therapeutic-equivalence code from the Orange Book.
- A missing patent or exclusivity row is not proof that no relevant rights exist, and listed patent information is not a freedom-to-operate opinion.
- Approved uses, dosing, warnings, and clinical evidence require the exact current product label or approval package and are not inferred from the reference product.
Change history
Record versions
- v4Jul 02, 2026
- v3Jul 02, 2026
- v2Jul 02, 2026
PegIntron/ Rebetol Combo Pack: frequently asked questions
Licensure, biosimilar status, exclusivity, and patents for this biologic, from the FDA Purple Book.
Built directly from the FDA Purple Book database of licensed biological products. License types, approval and exclusivity dates, and the patent list match the official FDA record. The Purple Book patent list reflects the statutory BPCIA patent exchange and is not exhaustive.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
